Pathogenesis and Management of Aspirin-Intolerant Asthma

Vane SJ. Aspirin and other anti-inflammatory drugs. Thorax 2000; 55 Suppl. 2: S3–9 Widal F, Abrami P, Lermoyez J. First complete description of the aspirin idiosyncrasy-asthma-nasal polyposis syndrome (plus urticaria): 1922 (with a note on aspirin desensitization). J Asthma 1987; 24: 297–300 Samter M, Beers Jr RF. Intolerance to aspirin: clinical studies and consideration of its pathogenesis. Ann Intern Med 1968; 68: 975–83 Szczeklik A, Stevenson DD. Aspirin-induced asthma: advances in pathogenesis and management. J Allergy Clin Immunol 1999; 104: 5–13 Settipane GA. Aspirin sensitivity and allergy. Biomed Pharmacother 1988; 42: 493–8 Quiralte J, Blanco C, Castillo R, et al. Intolerance to nonsteroidal antiinflammatory drugs: results of controlled drug challenges in 98 patients. J Allergy Clin Immunol 1996; 98: 678–85 Stevenson DD, Hankammer MA, Mathison DA, et al. Aspirin desensitization treatment of aspirin-sensitive patients with rhinosinusitis-asthma: long-term outcomes. J Allergy Clin Immunol 1996; 98: 751–8 Christie PE, Tagari P, Ford Hutchinson AW, et al. Urinary leukotriene E4 concentrations increase after aspirin challenge in aspirin-sensitive asthmatic subjects. Am Rev Respir Dis 1991; 143: 1025–9 Kalyoncu AF, Karakaya G, Sahin AA, et al. Occurrence of allergic conditions in asthmatics with analgesic intolerance. Allergy 1999; 54: 428–35 Hedman J, Kaprio J, Poussa T, et al. Prevalence of asthma, aspirin intolerance, nasal polyposis and chronic obstructive pulmonary disease in a population-based study. Int J Epidemiol 1999; 28: 717–22 McDonald JR, Mathison DA, Stevenson DD. Aspirin intolerance in asthma: detection by oral challenge. J Allergy Clin Immunol 1972; 50: 198–207 Vally H, Taylor ML, Thompson PJ. The prevalence of aspirin intolerant asthma (AIA) in Australian asthmatic patients. Thorax 2002; 57: 569–74 Johnson AG, Day RO. The problems and pitfalls of NSAID therapy in the elderly (Part I). Drugs Aging 1991; 1: 130–43 Faich GA. Adverse-drug-reaction monitoring. N Engl J Med 1986; 314: 1589–92 Szczeklik A, Nizankowska E, Duplaga M. Natural history of aspirin-induced asthma. AIANE Investigators. European Network on Aspirin-Induced Asthma. Eur Respir J 2000; 16: 432–6 Marquette CH, Saulnier F, Leroy O, et al. Long-term prognosis of near-fatal asthma: a 6-year follow-up study of 145 asthmatic patients who underwent mechanical ventilation for a near-fatal attack of asthma. Am Rev Respir Dis 1992; 146: 76–81 Matsuse H, Shimoda T, Matsuo N, et al. Aspirin-induced asthma as a risk factor for asthma mortality. J Asthma 1997; 34: 413–7 Bochenek G, Szczeklik A, Niz Ankowska E. Testing for aspirin hypersensitivity. Allergy 2002; 57: 562–5 Melillo G, Balzano G, Bianco S, et al. Report of the INTERASMA Working Group on Standardization of Inhalation Provocation Tests in Aspirin-induced Asthma: oral and inhalation provocation tests for the diagnosis of aspirin-induced asthma. Allergy 2001; 56: 899–911 Melillo G, Bonini S, Cocco G, et al. EAACI provocation tests with allergens: report prepared by the European Academy of Allergology and Clinical Immunology Subcommittee on provocation tests with allergens. Allergy 1997; 52: 1–35 Martelli NA. Bronchial and intravenous provocation tests with indomethacin in aspirin-sensitive asthmatics. Am Rev Respir Dis 1979; 120: 1073–9 Mita H, Endoh S, Kudoh M, et al. Possible involvement of mast-cell activation in aspirin provocation of aspirin-induced asthma. Allergy 2001; 56: 1061–7 Kawagishi Y, Mita H, Taniguchi M, et al. Leukotriene C4 synthase promoter polymorphism in Japanese patients with aspirin-induced asthma. J Allergy Clin Immunol 2002; 109: 936–42 Obase Y, Shimoda T, Tomari SY, et al. Effects of pranlukast on chemical mediators in induced sputum on provocation tests in atopic and aspirin-intolerant asthmatic patients. Chest 2002; 121: 143–50 Bianco S, Robuschi M, Petrigni G. Apsirin sensitivity in asthmatics. Br Med J 1981; 282: 146 Nizankowska E, Cmiel A, Bestynska Krypel A, et al. Oral and bronchial provocation tests with aspirin for diagnosis of aspirin-induced asthma. Eur Respir J 2000; 15: 863–9 Melillo G, Padovano A, Cocco G, et al. Dosimeter inhalation test with lysine acetylsalicylate for the detection of aspirin-induced asthma. Ann Allergy 1993; 71: 61–5 Dahlen B, Melillo G. Inhalation challenge in aspirin-induced asthma. Respir Med 1998; 92: 378–84 Phillips GD, Foord R, Holgate ST. Inhaled lysine-aspirin as a bronchoprovocation procedure in aspirin-sensitive asthma: its repeatability, absence of a late-phase reaction, and the role of histamine. J Allergy Clin Immunol 1989; 84: 232–41 Casadevall J, Ventura PJ, Mullol J, et al. Intranasal challenge with aspirin in the diagnosis of aspirin intolerant asthma: evaluation of nasal response by acoustic rhinometry. Thorax 2000; 55: 921–4 Bochenek G, Nizankowska E, Szczeklik A. The atopy trait in hypersensitivity to nonsteroidal anti-inflammatory drugs. Allergy 1996; 51: 16–23 Szczeklik A, Gryglewski RJ, Czerniawska Mysik G. Relationship of inhibition of prostaglandin biosynthesis by analgesics to asthma attacks in aspirin-sensitive patients. BMJ 1975; 1: 67–9 Nasser SM, Pfister R, Christie PE, et al. Inflammatory cell populations in bronchial biopsies from aspirin-sensitive asthmatic subjects. Am J Respir Crit Care Med 1996; 153: 90–6 Sousa AR, Lams BE, Pfister R, et al. Expression of interleukin-5 and granulocyte-macrophage colony-stimulating factor in aspirin-sensitive and non-aspirin-sensitive asthmatic airways. Am J Respir Crit Care Med 1997; 156: 1384–9 Cowburn AS, Sladek K, Soja J, et al. Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma. J Clin Invest 1998; 101: 834–46 Hawkey CJ. COX-2 inhibitors. Lancet 1999; 353: 307–14 Funk CD. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 2001; 294: 1871–5 Jawien J. A new insight into aspirin-induced asthma. Eur J Clin Invest 2002; 32: 134–8 Szczeklik A. The cyclooxygenase theory of aspirin-induced asthma. Eur Respir J 1990; 3: 588–93 Picado C, Juan M, Fernandez Morata JC, et al. Cyclooxygenase-2 mRNA is downexpressed in nasal polyps from aspirin-sensitive asthmatics. Am J Respir Crit Care Med 1999; 160: 291–6 Sampson AP, Cowburn AS, Sladek K, et al. Profound overexpression of leukotriene C4 synthase in bronchial biopsies from aspirin-intolerant asthmatic patients. Int Arch Allergy Immunol 1997; 113: 355–7 Sousa A, Pfister R, Christie PE, et al. Enhanced expression of cyclo-oxygenase isoenzyme 2 (COX-2) in asthmatic airways and its cellular distribution in aspirin-sensitive asthma. Thorax 1997; 52: 940–5 Picado C. Aspirin-intolerant asthma: role of cyclo-oxygenase enzymes. Allergy 2002; 57 Suppl. 72: 58–60 Holgate ST, Burns GB, Robinson C, et al. Anaphylactic- and calcium-dependent generation of prostaglandin D2 (PGD2), thromboxane B2, and other cyclooxygenase products of arachidonic acid by dispersed human lung cells and relationship to histamine release. J Immunol 1984; 133: 2138–44 Higashi N, Taniguchi M, Mita H, et al. A comparative study of eicosanoid concentrations in sputum and urine in patients with aspirin-intolerant asthma. Clin Exp Allergy 2002; 32: 1484–90 Szczeklik A, Sladek K, Dworski R, et al. Bronchial aspirin challenge causes specific eicosanoid response in aspirin-sensitive asthmatics. Am J Respir Crit Care Med 1996; 154: 1608–14 Szczeklik A, Mastalerz L, Nizankowska E, et al. Protective and bronchodilator effects of prostaglandin E and salbutamol in aspirin-induced asthma. Am J Respir Crit Care Med 1996; 153: 567–71 Sestini P, Armetti L, Gambaro G, et al. Inhaled PGE2 prevents aspirin-induced bronchoconstriction and urinary LTE4 excretion in aspirin-sensitive asthma. Am J Respir Crit Care Med 1996; 153: 572–5 Kuehl Jr FA, Dougherty HW, Ham EA. Interactions between prostaglandins and leukotrienes. Biochem Pharmacol 1984; 33: 1–5 Christman BW, Christman JW, Dworski R, et al. Prostaglandin E2 limits arachidonic acid availability and inhibits leukotriene B4 synthesis in rat alveolar macrophages by a nonphospholipase A2 mechanism. J Immunol 1993; 151: 2096–104 Schafer D, Schmid M, Gode UC, et al. Dynamics of eicosanoids in peripheral blood cells during bronchial provocation in aspirin-intolerant asthmatics. Eur Respir J 1999; 13: 638–46 Kowalski ML, Pawliczak R, Wozniak J, et al. Differential metabolism of arachidonic acid in nasal polyp epithelial cells cultured from aspirin-sensitive and aspirin-tolerant patients. Am J Respir Crit Care Med 2000; 161: 391–8 Sladek K, Dworski R, Soja J, et al. Eicosanoids in bronchoalveolar lavage fluid of aspirin-intolerant patients with asthma after aspirin challenge. Am J Respir Crit Care Med 1994; 149: 940–6 Picado C, Ramis I, Rosello J, et al. Release of peptide leukotriene into nasal secretions after local instillation of aspirin in aspirin-sensitive asthmatic patients. Am Rev Respir Dis 1992; 145: 65–9 Lanmack EL, Wenzel SE. Mast cell and eosinophil responses after indomethacin in asthmatics tolerant and intolerant to aspirin. In: Szczeklik A, Gryglewski RJ, Vane JR, editors. Eicosanoids, aspirin, and asthma. New York: Marcel Dekker, 1998: 337–50 Sanak M, Sampson AP. Biosynthesis of cysteinyl-leucotrienes in aspirin-intolerant asthma. Clin Exp Allergy 1999; 29: 306–13 Abramovitz M, Wong E, Cox ME, et al. 5-lipoxygenase-activating protein stimulates the utilization of arachidonic acid by 5-lipoxygenase. Eur J Biochem 1993; 215: 105–11 In KH, Asano K, Beier D, et al. Naturally occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription. J Clin Invest 1997; 99: 1130–7 Kellaway CH, Trethewie WR. The liberation of a slow reacting smoth muscle-stimulating substance in anaphylaxis Q J Exp Physiol 1940; 30: 121–45 Murphy RC, Hammarstrom S, Samuelsson B. Leukotriene C: a slow-reacting substance from murine mastocytoma cells. Proc Natl Acad Sci U S A 1979; 76: 4275–9 Radmark O, Malmsten C, Samuelsson B. Leukotriene A4: enzymatic conversion to leukotriene C4. Biochem Biophys Res Commun 1980; 96: 1679–87 Peters Golden M, Brock TG. Intracellular compartmentalization of leukotriene biosynthesis. Am J Respir Crit Care Med 2000; 161: S36–40 Bach MK, Brashler JR, Morton DR. Solubilization and characterization of the leukotriene C4 synthetase of rat basophil leukemia cells: a novel, particulate glutathione S-transferase. Arch Biochem Biophys 1984; 230: 455–65 Lynch KR, O’Neill GP, Liu Q, et al. Characterization of the human cysteinyl leukotriene CysLT1 receptor. Nature 1999; 399: 789–93 Takasaki J, Kamohara M, Matsumoto M, et al. The molecular characterization and tissue distribution of the human cysteinyl leukotriene CysLT(2) receptor. Biochem Biophys Res Commun 2000; 274: 316–22 Lewis RA, Austen KF, Soberman RJ. Leukotrienes and other products of the 5-lipoxygenase pathway: biochemistry and relation to pathobiology in human diseases. N Engl J Med 1990; 323: 645–55 Holgate ST, Bradding P, Sampson AP. Leukotriene antagonists and synthesis inhibitors: new directions in asthma therapy. J Allergy Clin Immunol 1996; 98: 1–13 Kumlin M, Dahlen B, Bjorck T, et al. Urinary excretion of leukotriene E4 and 11-dehydro-thromboxane B2 in response to bronchial provocations with allergen, aspirin, leukotriene D4, and histamine in asthmatics. Am Rev Respir Dis 1992; 146: 96–103 Israel E, Fischer AR, Rosenberg MA, et al. The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin. Am Rev Respir Dis 1993; 148: 1447–51 Obase Y, Shimoda T, Tomari S, et al. Effects of pranlukast on aspirin-induced bronchoconstriction: differences in chemical mediators between aspirin-intolerant and tolerant asthmatic patients. Ann Allergy Asthma Immunol 2001; 87: 74–9 Antczak A, Montuschi P, Kharitonov S, et al. Increased exhaled cysteinyl-leukotrienes and 8-isoprostane in aspirin-induced asthma. Am J Respir Crit Care Med 2002; 166: 301–6 Dahlen B, Margolskee DJ, Zetterstrom O, et al. Effect of the leukotriene receptor antagonist MK-0679 on baseline pulmonary function in aspirin sensitive asthmatic subjects. Thorax 1993; 48: 1205–10 Pavord ID, Tattersfield AE. Bronchoprotective role for endogenous prostaglandin E2. Lancet 1995; 345: 436–8 Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971; 231: 232–5 Penrose JF, Baldasaro MH. Leukotriene C4 synthase: a candidate gene for the aspirin-intolerant asthmatic phenotype. Allergy Asthma Proc 1999; 20: 353–60 Sanak M, Simon HU, Szczeklik A. Leukotriene C4 synthase promoter polymorphism and risk of aspirin-induced asthma. Lancet 1997; 350: 1599–600 Sanak M, Pierzchalska M, Bazan Socha S, et al. Enhanced expression of the leukotriene C(4) synthase due to overactive transcription of an allelic variant associated with aspirin-intolerant asthma. Am J Respir Cell Mol Biol 2000; 23: 290–6 Van Sambeek R, Stevenson DD, Baldasaro M, et al. 5′ flanking region polymorphism of the gene encoding leukotriene C4 synthase does not correlate with the aspirin-intolerant asthma phenotype in the United States. J Allergy Clin Immunol 2000; 106: 72–6 Sanak M, Szczeklik A. Leukotriene C4 synthase polymorphism and aspirin-induced asthma. J Allergy Clin Immunol 2001; 107: 561–2 Asano K, Shiomi T, Hasegawa N, et al. Leukotriene C4 synthase gene A(−444)C polymorphism and clinical response to a CYS-LT(1) antagonist, pranlukast, in Japanese patients with moderate asthma. Pharmacogenetics 2002; 12: 565–70 Arm JP, O’Hickey SP, Spur BW, et al. Airway responsiveness to histamine and leukotriene E4 in subjects with aspirin-induced asthma. Am Rev Respir Dis 1989; 140: 148–53 Sousa AR, Parikh A, Scadding G, et al. Leukotriene-receptor expression on nasal mucosal inflammatory cells in aspirin-sensitive rhinosinusitis. N Engl J Med 2002; 347: 1493–9 Christie PE, Spur BW, Schmitz Schumann M, et al. Airway responsiveness to leukotriene C4 (LTC4), leukotriene E4 (LTE4) and histamine in aspirin-sensitive asthmatic subjects. Eur Respir J 1993; 6: 1468–73 Arm JP, Austen KF. Leukotriene receptors and aspirin sensitivity. N Engl J Med 2002; 347: 1524–6 Dworski R, Sheller JR. Urinary mediators and asthma. Clin Exp Allergy 1998; 28: 1309–12 Serhan CN, Oliw E. Unorthodox routes to prostanoid formation: new twists in cyclooxygenase-initiated pathways. J Clin Invest 2001; 107: 1481–9 Mitchell JA, Belvisi MG. Too many COX (cyclo-oxygenase) spoil the broth: aspirin-sensitive asthma and 5-lypoxygenase. Thorax 1997; 52: 933–5 Sanak M, Levy BD, Clish CB, et al. Aspirin-tolerant asthmatics generate more lipoxins than aspirin-intolerant asthmatics. Eur Respir J 2000; 16: 44–9 Levy BD, Devchand PR, De Sanctis GT, et al. Multi-pronged inhibition of airway hyper-responsiveness and inflammation by lipoxin A(4). Nat Med 2002; 8: 1018–23 Szczeklik A. Aspirin-induced asthma as a viral disease. Clin Allergy 1988; 18: 15–20 Levy M. Role of viral infections in the induction of adverse drug reactions. Drug Saf 1997; 16: 1–8 Yoshida S, Sakamoto H, Yamawaki Y, et al. Effect of acyclovir on bronchoconstriction and urinary leukotriene E4 excretion in aspirin-induced asthma. J Allergy Clin Immunol 1998; 102: 909–14 Lassalle P, Delneste Y, Gosset P, et al. T and B cell immune response to a 55-kDa endothelial cell-derived antigen in severe asthma. Eur J Immunol 1993; 23: 796–803 Szczeklik A, Musial J, Pulka G. Autoimmune vasculitis and aortic stenosis in aspirin-induced asthma (AIA). Allergy 1997; 52: 352–4 Szczeklik A, Nizankowska E, Schmitz Schumann M, et al. Altered distribution of IgG subclasses in aspirin-induced asthma: high IgG4, low IgG1. Clin Exp Allergy 1992; 22: 283–7 Dekker JW, Nizankowska E, Schmitz Schumann M, et al. Aspirin-induced asthma and HLA-DRB1 and HLA-DPB1 genotypes. Clin Exp Allergy 1997; 27: 574–7 Global initiative for asthma. Global strategy for asthma management and prevention: a practical guide for public health officials and health care professionals. Bethesda (MD): NIH Publication No. 02-3659 2002 Drazen JM, Israel E, O’Byrne PM. Treatment of asthma with drugs modifying the leukotriene pathway. N Engl J Med 1999; 340: 197–206 Lipworth BJ. Leukotriene-receptor antagonists. Lancet 1999; 353: 57–62 Babu KS, Salvi SS. Aspirin and asthma. Chest 2000; 118: 1470–6 Dahlen B, Nizankowska E, Szczeklik A, et al. Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics. Am J Respir Crit Care Med 1998; 157: 1187–94 Sebaldt RJ, Sheller JR, Oates JA, et al. Inhibition of eicosanoid biosynthesis by glucocorticoids in humans. Proc Natl Acad Sci U S A 1990; 87: 6974–8 Tomari S, Matsuse H, Machida I, et al. Pranlukast, a cysteinyl leukotoriene receptor 1 antagonist, atenuates allergen specific TNF-alpha production and NF-kappaB nuclear translocation in peripheral blood monocytes from atopic asthmatics Clin Exp Allergy 2003 Jun; 33(6): 795–801 Manso G, Baker AJ, Taylor IK, et al. In vivo and in vitro effects of glucocorticosteroids on arachidonic acid metabolism and monocyte function in nonasthmatic humans. Eur Respir J 1992; 5: 712–6 O’Shaughnessy KM, Wellings R, Gillies B, et al. Differential effects of fluticasone propionate on allergen-evoked bronchoconstriction and increased urinary leukotriene E4 excretion. Am Rev Respir Dis 1993; 147: 1472–6 Dworski R, Fitzgerald GA, Oates JA, et al. Effect of oral prednisone on airway inflammatory mediators in atopic asthma. Am J Respir Crit Care Med 1994; 149: 953–9 Aksoy MO, Li X, Borenstein M, et al. Effects of topical corticosteroids on inflammatory mediator-induced eicosanoid release by human airway epithelial cells. J Allergy Clin Immunol 1999; 103: 1081–91 Tomari S, Shimoda T, Kawano T, et al. Effects of pranlukast, a cysteinyl leukotriene receptor 1 antagonist, combined with inhaled beclomethasone in patients with moderate or severe asthma. Ann Allergy Asthma Immunol 2001; 87: 156–61 Dahlen B. Treatment of aspirin-intolerant asthma with antileukotrienes. Am J Respir Crit Care Med 2000; 161: S137–41 Dahlen SE, Malmstrom K, Nizankowska E, et al. Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trial. Am J Respir Crit Care Med 2002; 165: 9–14 Dahlen B, Nizankowska E, Szczeklik A. Benefits from adding the 5-lipoxgenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics. Am J Respirt Crit Care Med 1998; 157: 1187–94 Ragab S, Parikh A, Darby YC, et al. An open audit of montelukast, a leukotriene receptor antagonist, in nasal polyposis associated with asthma. Clin Exp Allergy 2001; 31: 1385–91 Mastalerz L, Nizankowska E, Sanak M, et al. Clinical and genetic features underlying the response of patients with bronchial asthma to treatment with a leukotriene receptor antagonist. Eur J Clin Invest 2002; 32: 949–55 Mastalerz L, Nizankowska E, Gawlewicz Mroczka A, et al. Protection against exercise-induced bronchoconstriction by montelukast in aspirin-sensitive and aspirin-tolerant patients with asthma. Clin Exp Allergy 2002; 32: 1360–5 NAEPP Expert Panel. Guidelines for the Diagnosis and Management of Asthma: Update on Selected Topics 2002. Bethesda (MD): National Institutes of Health 1997; NIH publication no. 97-4051 Demoly P, Jaffuel D, Mathieu M, et al. Glucocorticoid insensitive asthma: a one year clinical follow up pilot study. Thorax 1998; 53: 1063–5 Greening AP, Ind PW, Northfield M, et al. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group. Lancet 1994; 344: 219–24 Woolcock A, Lundback B, Ringdal N, et al. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med 1996; 153: 1481–8 Pauwels RA, Lofdahl CG, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma: Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 1997; 337: 1405–11 Wechsler ME, Garpestad E, Flier SR, et al. Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with asthma receiving zafirlukast. JAMA 1998; 279: 455–7 Guilpain P, Viallard JF, Lagarde P, et al. Churg-Strauss syndrome in two patients receiving montelukast. Rheumatology (Oxford) 2002; 41: 535–9 Churg J, Churg A. Zafirlukast and Churg-Strauss syndrome. JAMA 1998; 279: 1949–50 Green RL, Vayonis AG. Churg-Strauss syndrome after zafirlukast in two patients not receiving systemic steroid treatment. Lancet 1999; 353: 725–6 Bianco S, Robuschi M, Petrigni G, et al. Efficacy and tolerability of nimesulide in asthmatic patients intolerant to aspirin. Drugs 1993; 46 Suppl. 1: 115–20 Kosnik M, Music E, Matjaz F, et al. Relative safety of meloxicam in NSAID-intolerant patients. Allergy 1998; 53: 1231–3 Szczeklik A, Nizankowska E, Bochenek G, et al. Safety of a specific COX-2 inhibitor in aspirin-induced asthma. Clin Exp Allergy 2001; 31: 219–25 Gyllfors P, Bochenek G, Overholt J, et al. Biochemical and clinical evidence that aspirin-intolerant ashtmatic subjects tolerate that cyclooxygenase 2-selective analgetic drug celecoxib. J Allergy Clin Immunol 2003; 111: 142 Martin-Garcia C, Hinojosa M, Berges P, et al. Safety of a cyclooxygenase-2 inhibitor in patients with aspirin-sensitive asthma. Chest 2002; 121: 1812–7 Woessner KM, Simon RA, Stevenson DD. The safety of celecoxib in patients with aspirin-sensitive asthma. Arthritis Rheum 2002; 46: 2201–6 Walenga RW, Kester M, Coroneos E, et al. Constitutive expression of prostaglandin endoperoxide G/H synthetase (PGHS)-2 but not PGHS-1 in human tracheal epithelial cells in vitro. Prostaglandins 1996; 52: 341–59 Tocco G, Freire Moar J, Schreiber SS, et al. Maturational regulation and regional induction of cyclooxygenase-2 in rat brain: implications for Alzheimer’s disease. Exp Neurol 1997; 144: 339–49 Zimmermann KC, Sarbia M, Schror K, et al. Constitutive cyclooxygenase-2 expression in healthy human and rabbit gastric mucosa. Mol Pharmacol 1998; 54: 536–40 Petkova DK, Pang L, Range SP, et al. Immunocytochemical localization of cyclo-oxygenase isoforms in cultured human airway structural cells. Clin Exp Allergy 1999; 29: 965–72 Langenbach R, Morham SG, Tiano HF, et al. Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell 1995; 83: 483–92 Fitzgerald GA. Coxibs and cardiovascular disease. N Engl J Med 2004; 21(351): 1709–11 Settipane RA, Schrank PJ, Simon RA, et al. Prevalence of cross-sensitivity with acetaminophen in aspirin-sensitive asthmatic subjects. J Allergy Clin Immunol 1995; 96: 480–5 Chandrasekharan NV, Dai H, Roos KL, et al. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci U S A 2002; 99: 13926–31 Babu KS, Salvi SS. Aspirin and asthma. Chest 2000; 118: 1470–6 Chiu JT. Improvement in aspirin-sensitive asthmatic subjects after rapid aspirin desensitization and aspirin maintenance (ADAM) treatment. J Allergy Clin Immunol 1983; 71: 560–7 Sweet JM, Stevenson DD, Simon RA, et al. Long-term effects of aspirin desensitization: treatment for aspirin-sensitive rhinosinusitis-asthma. J Allergy Clin Immunol 1990; 85: 59–65 Berges Gimeno MP, Simon RA, Stevenson DD. Long-term treatment with aspirin desensitization in asthmatic patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 2003; 111: 180–6 Schaefer OP, Gore JM. Aspirin sensitivity: the role for aspirin challenge and desensitization in postmyocardial infarction patients. Cardiology 1999; 91: 8–13 Szmidt M, Grzelewska Rzymowska I, Rozniecki J. Tolerance to aspirin in aspirin-sensitive asthmatics: methods of inducing the tolerance state and its influence on the course of asthma and rhinosinusitis. J Investig Allergol Clin Immunol 1993; 3: 156–9 Pleskow WW, Stevenson DD, Mathison DA, et al. Aspirin desensitization in aspirin-sensitive asthmatic patients: clinical manifestations and characterization of the refractory period. J Allergy Clin Immunol 1982; 69: 11–9 Juergens UR, Christiansen SC, Stevenson DD, et al. Inhibition of monocyte leukotriene B4 production after aspirin desensitization. J Allergy Clin Immunol 1995; 96: 148–56 Nasser SM, Patel M, Bell GS, et al. The effect of aspirin desensitization on urinary leukotriene E4 concentrations in aspirin-sensitive asthma. Am J Respir Crit Care Med 1995; 151: 1326–30 Szczeklik A, Nizankowska E, Czerniawska Mysik G, et al. Hydrocortisone and airflow impairment in aspirin-induced asthma. J Allergy Clin Immunol 1985; 76: 530–6 Nakamura H, Matsuse H, Obase Y, et al. Clinical evaluation of anaphylactic reactions to intravenous corticosteroids in adult asthmatics. Respiration 2002; 69: 309–13 Goldstein DA, Zimmerman B, Spielberg SP. Anaphylactic response to hydrocortisone in childhood: a case report. Ann Allergy 1985; 55: 599–600 Preuss L. Allergic reactions to systemic glucocorticoids: a review. Ann Allergy 1985; 55: 772–5 Feigenbaum BA, Stevenson DD, Simon RA. Hydrocortisone sodium succinate does not cross-react with aspirin in aspirin-sensitive patients with asthma. J Allergy Clin Immunol 1995; 96: 545–8 Comaish S. A case of hypersensitivity to corticosteroids. Br J Dermatol 1969; 81: 919–25